Pulmonx (NASDAQ:LUNG) Shares Up 0.6% - Here's Why

Key Points

• Pulmonx Corporation's stock rose by 0.6% to $1.59, with a trading volume of 247,255 shares, which is down 25% from the average.
• Analysts have mixed ratings for Pulmonx, with estimates ranging from a high of $16 to a low of $2.50, reflecting a general average target of $7.66.
• The company has a market cap of $64.79 million, negative earnings per share of -$0.38, and is expected to post -1.55 EPS for the current year.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report)'s stock price shot up 0.6% during trading on Monday . The company traded as high as $1.63 and last traded at $1.59. 247,255 shares were traded during mid-day trading, a decline of 25% from the average session volume of 328,108 shares. The stock had previously closed at $1.58.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LUNG. D. Boral Capital reiterated a "buy" rating and issued a $16.00 target price on shares of Pulmonx in a research report on Monday, September 8th. Stifel Nicolaus decreased their target price on shares of Pulmonx from $16.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, July 31st. Piper Sandler cut shares of Pulmonx from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $9.00 to $2.50 in a research report on Thursday, July 31st. Wall Street Zen cut shares of Pulmonx from a "hold" rating to a "sell" rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Pulmonx in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $7.66.

Pulmonx Stock Performance

The firm has a market cap of $64.79 million, a P/E ratio of -1.11 and a beta of 0.42. The company has a current ratio of 5.35, a quick ratio of 4.63 and a debt-to-equity ratio of 0.54. The business's fifty day simple moving average is $1.67 and its 200-day simple moving average is $2.98.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. The business had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pulmonx Corporation will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On Pulmonx

A number of large investors have recently modified their holdings of LUNG. Corton Capital Inc. bought a new stake in shares of Pulmonx during the 2nd quarter valued at about $32,000. R Squared Ltd bought a new stake in shares of Pulmonx during the 2nd quarter valued at about $41,000. Bank of Montreal Can bought a new stake in shares of Pulmonx during the 2nd quarter valued at about $53,000. Vontobel Holding Ltd. bought a new stake in shares of Pulmonx during the 1st quarter valued at about $82,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Pulmonx during the 2nd quarter valued at about $84,000. Institutional investors own 91.04% of the company's stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.